Jonathan W. Friedberg

30.3k total citations · 3 hit papers
393 papers, 12.7k citations indexed

About

Jonathan W. Friedberg is a scholar working on Pathology and Forensic Medicine, Oncology and Genetics. According to data from OpenAlex, Jonathan W. Friedberg has authored 393 papers receiving a total of 12.7k indexed citations (citations by other indexed papers that have themselves been cited), including 337 papers in Pathology and Forensic Medicine, 172 papers in Oncology and 139 papers in Genetics. Recurrent topics in Jonathan W. Friedberg's work include Lymphoma Diagnosis and Treatment (331 papers), Chronic Lymphocytic Leukemia Research (134 papers) and Viral-associated cancers and disorders (92 papers). Jonathan W. Friedberg is often cited by papers focused on Lymphoma Diagnosis and Treatment (331 papers), Chronic Lymphocytic Leukemia Research (134 papers) and Viral-associated cancers and disorders (92 papers). Jonathan W. Friedberg collaborates with scholars based in United States, Canada and France. Jonathan W. Friedberg's co-authors include Richard I. Fisher, Andrew D. Zelenetz, Carla Casulo, Christopher R. Flowers, Ann S. LaCasce, Brian K. Link, Michael LeBlanc, John P. Leonard, Bruce D. Cheson and James R. Cerhan and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Jonathan W. Friedberg

377 papers receiving 12.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era

2013 609 citations Leo I. Gordon, Andrew D. Zelenetz et al. Blood profile →
Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia

2009 590 citations Jonathan W. Friedberg, Jeff P. Sharman et al. Blood profile →
Early Relapse of Follicular Lymphoma After Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Defines Patients at High Risk for Death: An Analysis From the National LymphoCare Study

2015 509 citations Carla Casulo, Michelle Byrtek et al. Journal of Clinical Oncology profile →

Peers

Countries citing papers authored by Jonathan W. Friedberg

Since Specialization

Citations

This map shows the geographic impact of Jonathan W. Friedberg's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jonathan W. Friedberg with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jonathan W. Friedberg more than expected).

Fields of papers citing papers by Jonathan W. Friedberg

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jonathan W. Friedberg. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jonathan W. Friedberg. The network helps show where Jonathan W. Friedberg may publish in the future.

Co-authorship network of co-authors of Jonathan W. Friedberg

This figure shows the co-authorship network connecting the top 25 collaborators of Jonathan W. Friedberg. A scholar is included among the top collaborators of Jonathan W. Friedberg based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jonathan W. Friedberg. Jonathan W. Friedberg is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	High‐dose vitamin D to attenuate bone loss in patients with prostate cancer on androgen deprivation therapy: A phase 2 RCT 2024 ·Cancer ·Luke J. Peppone, Amber S. Kleckner, Chunkit Fung, J. Edward Puzas, (unknown), Eva Culakova, Julia E. Inglis, Charles Kamen, Jonathan W. Friedberg, Michelle C. Janelsins, Karen M. Mustian, Charles E. Heckler, Supriya G. Mohile	6
2	Trial in Progress - Alliance A052101: A Randomized Phase 3 Trial of Continuous Vs. Intermittent Maintenance Therapy with Zanubrutinib As Upfront Treatment in Older Patients with Mantle Cell Lymphoma 2024 ·Blood ·Anne Beaven, Susan M. Geyer, Jonathon B. Cohen, Tycel Phillips, Travis Dockter, Priyanka A. Pophali, Gita Thanarajasingam, Gina L. Mazza, Alvaro J. Alencar, Shira Dinner, Eric D. Hsi, M.X. Welliver, Daniel A. Nikcevich, Brad S. Kahl, Jonathan W. Friedberg, Nancy L. Bartlett, John P. Leonard	0
3	Vitamin D in patients with low tumor-burden indolent non-Hodgkin lymphoma treated with rituximab therapy (ILyAD): a randomized, phase 3 clinical trial 2024 ·EClinicalMedicine ·Jonathan W. Friedberg, Michael T. Brady, Myla Strawderman, Brad S. Kahl, Izidore S. Lossos, Jonathon B. Cohen, Patrick M. Reagan, Carla Casulo, (unknown), Andrea Baran, Grerk Sutamtewagul, Paul M. Barr, John P. Leonard, John M. Ashton, John Strang, Francisco Vega, Derick R. Peterson, Loretta J. Nastoupil	3
4	A “FUNCTIONAL CURE” MAY BE ACHIEVABLE IN A SUBSET OF PATIENTS WITH FOLLICULAR LYMPHOMA TREATED WITH CHEMOIMMUNOTHERAPY: 15‐YEAR FOLLOW‐UP OF PHASE III SWOG‐S0016 2023 ·Hematological Oncology ·Mazyar Shadman, (unknown), Lisa M. Rimsza, John P. Leonard, Mark Kaminski, Catherine Spier, Ajay K. Gopal, Shaker R. Dakhil, Michael LeBlanc, Sonali M. Smith, Jonathan W. Friedberg	1
5	Minimal Residual Disease (MRD) Status Predicts Outcomes in Patients with Follicular Lymphoma (FL) Treated with Chemo-Immunotherapy on SWOG S0016 2023 ·Blood ·Alexey V. Danilov, Hongli Li, Mazyar Shadman, Lisa M. Rimsza, Ahmad S. Zebari, Sonali M. Smith, Michael LeBlanc, Jonathan W. Friedberg, Christopher S. Carlson, Joo Y. Song	0
6	T-Cell–Rich Hodgkin Lymphoma With Features of Classic Hodgkin Lymphoma and Nodular Lymphocyte-Predominant Hodgkin Lymphoma: A Borderline Category With Overlapping Morphologic and Immunophenotypic Features 2023 ·Archives of Pathology & Laboratory Medicine ·Siba El Hussein, Hong Fang, Fatima Zahra Jelloul, Wei Wang, Sanam Loghavi, Roberto N. Miranda, Jonathan W. Friedberg, Richard Burack, Andrew G. Evans, Jie Xu, L. Jeffrey Medeiros	1
7	Subclonal TP53 mutations are frequent and predict resistance to radioimmunotherapy in follicular lymphoma 2023 ·Blood Advances ·Richard Burack, Hongli Li, Diana G. Adlowitz, (unknown), Lisa M. Rimsza, Mazyar Shadman, Catherine Spier, Mark Kaminski, John P. Leonard, Michael LeBlanc, Sonali M. Smith, Jonathan W. Friedberg	6
8	Prognostication for Advanced Stage Hodgkin Lymphoma (HL) in the Modern Era: A Project from the Hodgkin Lymphoma International Study for Individual Care (HoLISTIC) Consortium 2020 ·Blood ·Angie Mae Rodday, Susan K. Parsons, (unknown), Ranjana H. Advani, Massimo Federico, Jonathan W. Friedberg, Andrea Gallamini, David Hodgson, Peter Hoskin, Martin Hutchings, Peter Johnson, Kara M. Kelly, Brian K. Link, John Radford, Pier Luigi Zinzani, James R. Cerhan, John Raemaekers, Andrew M. Evens	3
9	Brentuximab Vedotin plus Chemotherapy in North American Subjects with Newly Diagnosed Stage III or IV Hodgkin Lymphoma 2019 ·Clinical Cancer Research ·Radhakrishnan Ramchandren, Ranjana H. Advani, Stephen M. Ansell, Nancy L. Bartlett, Robert Chen, Joseph M. Connors, Tatyana Feldman, Andres Forero‐Torres, Jonathan W. Friedberg, Ajay K. Gopal, Leo I. Gordon, John Kuruvilla, Kerry J. Savage, Anas Younes, (unknown), Thomas Manley, Keenan Fenton, David J. Straus	30
10	In Situ Vaccination with a TLR9 Agonist and Local Low-Dose Radiation Induces Systemic Responses in Untreated Indolent Lymphoma 2018 ·Cancer Discovery ·Matthew J. Frank, Patrick M. Reagan, Nancy L. Bartlett, Leo I. Gordon, Jonathan W. Friedberg, Debra K. Czerwinski, Steven Long, Richard T. Hoppe, Robert S. Janssen, Albert F. Candia, Robert L. Coffman, Ronald Levy	142
11	How I treat double-hit lymphoma 2017 ·Blood ·Jonathan W. Friedberg	79
12	Phase II Intergroup Trial of Alisertib in Relapsed and Refractory Peripheral T-Cell Lymphoma and Transformed Mycosis Fungoides: SWOG 1108 2015 ·Journal of Clinical Oncology ·Paul M. Barr, Hongli Li, Catherine Spier, Daruka Mahadevan, Michael LeBlanc, Mansoor Ul Haq, (unknown), Christopher R. Flowers, Nina D. Wagner‐Johnston, Steven M. Horwitz, Richard I. Fisher, Bruce D. Cheson, Sonali M. Smith, Brad S. Kahl, Nancy L. Bartlett, Jonathan W. Friedberg	91
13	Early Relapse of Follicular Lymphoma After Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Defines Patients at High Risk for Death: An Analysis From the National LymphoCare Study breakdown → 2015 ·Journal of Clinical Oncology ·Carla Casulo, Michelle Byrtek, Keith Dawson, Xiaolei Zhou, Charles M. Farber, Christopher R. Flowers, John D. Hainsworth, Matthew J. Maurer, James R. Cerhan, Brian K. Link, Andrew D. Zelenetz, Jonathan W. Friedberg	509
14	Phase 2 study of frontline brentuximab vedotin monotherapy in Hodgkin lymphoma patients aged 60 years and older 2015 ·Blood ·Andres Forero‐Torres, Beata Holkova, Jerome H. Goldschmidt, Robert Chen, Gregg A. Olsen, Ralph V. Boccia, Rodolfo Bordoni, Jonathan W. Friedberg, Jeff P. Sharman, Maria Corinna Palanca-Wessels, Yinghui Wang, Christopher A. Yasenchak	95
15	Brentuximab Vedotin in Combination with Dacarbazine or Bendamustine for Frontline Treatment of Hodgkin Lymphoma in Patients Aged 60 Years and Above: Interim Results of a Multi-Cohort Phase 2 Study 2015 ·Blood ·Christopher A. Yasenchak, Andres Forero‐Torres, (unknown), Rodolfo Bordoni, Dipti Patel‐Donnelly, Patrick J. Flynn, Robert Chen, Abraham Fong, Jonathan W. Friedberg	12
16	PI3K/mTOR Inhibition Markedly Potentiates HDAC Inhibitor Activity in NHL Cells through BIM- and MCL-1–Dependent Mechanisms In Vitro and In Vivo 2014 ·Clinical Cancer Research ·Mohamed Rahmani, Mandy Mayo Aust, (unknown), (unknown), Jonathan W. Friedberg, Steven Grant	76
17	A Comparative Analysis of Prognostic Factor Models for Follicular Lymphoma Based on a Phase III Trial of CHOP–Rituximab versus CHOP + 131Iodine—Tositumomab 2013 ·Clinical Cancer Research ·Oliver W. Press, Joseph M. Unger, Lisa M. Rimsza, Jonathan W. Friedberg, Michael LeBlanc, Myron S. Czuczman, Mark Kaminski, Rita M. Braziel, Catherine Spier, Ajay K. Gopal, David G. Maloney, Bruce D. Cheson, Shaker R. Dakhil, Thomas P. Miller, Richard I. Fisher	32
18	Phase II Study of Alisertib, a Selective Aurora A Kinase Inhibitor, in Relapsed and Refractory Aggressive B- and T-Cell Non-Hodgkin Lymphomas 2013 ·Journal of Clinical Oncology ·Jonathan W. Friedberg, Daruka Mahadevan, (unknown), Daniel O. Persky, Izidore S. Lossos, Amit B. Agarwal, (unknown), Richard Burack, Xiaofei Zhou, E. Jane Leonard, Howard Fingert, Hadi Danaee, Steven H. Bernstein	161
19	Phase III Randomized Intergroup Trial of CHOP Plus Rituximab Compared With CHOP Chemotherapy Plus ¹³¹ Iodine-Tositumomab for Previously Untreated Follicular Non-Hodgkin Lymphoma: SWOG S0016 2012 ·Journal of Clinical Oncology ·Oliver W. Press, Joseph M. Unger, Lisa M. Rimsza, Jonathan W. Friedberg, Michael LeBlanc, Myron S. Czuczman, Mark Kaminski, Rita M. Braziel, Catherine Spier, Ajay K. Gopal, David G. Maloney, Bruce D. Cheson, Shaker R. Dakhil, Thomas P. Miller, Richard I. Fisher	123
20	Randomized Phase III Trial of ABVD Versus Stanford V With or Without Radiation Therapy in Locally Extensive and Advanced-Stage Hodgkin Lymphoma: An Intergroup Study Coordinated by the Eastern Cooperative Oncology Group (E2496) 2012 ·Journal of Clinical Oncology ·Leo I. Gordon, Fangxin Hong, Richard I. Fisher, Nancy L. Bartlett, Joseph M. Connors, Randy D. Gascoyne, Henry Wagner, Patrick J. Stiff, Bruce D. Cheson, Mary Gospodarowicz, Ranjana H. Advani, Brad S. Kahl, Jonathan W. Friedberg, Kristie A. Blum, Thomas M. Habermann, Joseph M. Tuscano, Richard T. Hoppe, Sandra J. Horning	194

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact